Radiofrequency ablation in the treatment of hepatocellular carcinoma

References

• Bruix J, Sherman M. American Association for the Study of Liver Diseases, American Association for the Study of Liver Disease. Management of hepatocellular carcinoma: an update. Hepatology. 2011;53(3):1020–1022.
   PubMed Web of Science ®Google Scholar
• Livraghi T, Goldberg SN, Lazzaroni S, et al. Small hepatocellular carcinoma: treatment with radio-frequency ablation versus ethanol injection. Radiology. 1999;210(3):655–661.
   PubMed Web of Science ®Google Scholar
• Livraghi T, Goldberg SN, Lazzaroni S, et al. Hepatocellular carcinoma: radio-frequency ablation of medium and large lesions. Radiology. 2000;214(3):761–768.
   PubMed Web of Science ®Google Scholar
• Lencioni R, Cioni D, Crocetti L, et al. Early-stage hepatocellular carcinoma in patients with cirrhosis: long-term results of percutaneous image-guided radiofrequency ablation. Radiology. 2005;234(3):961–967.
   PubMed Web of Science ®Google Scholar
• Bhattacharjya S, Bhattacharjya T, Quaglia A, et al. Liver transplantation in cirrhotic patients with small hepatocellular carcinoma: an analysis of pre-operative imaging, explant histology and prognostic histologic indicators. Dig Surg. 2004;21(2):152–159.
   PubMed Web of Science ®Google Scholar
• Facciorusso A, Del Prete V, Antonino M, et al. Post-recurrence survival in hepatocellular carcinoma after percutaneous radiofrequency ablation. Dig Liver Dis. 2014;46(11):1014–1019.
   PubMedGoogle Scholar
• Brunello F, Cantamessa A, Gaia S, et al. Radiofrequency ablation: technical and clinical long-term outcomes for single hepatocellular carcinoma up to 30 mm. Eur J Gastroenterol Hepatol. 2013;25(7):842–849.
   PubMed Web of Science ®Google Scholar
• Francica G, Saviano A, De Sio I, et al. Long-term effectiveness of radiofrequency ablation for solitary small hepatocellular carcinoma: a retrospective analysis of 363 patients. Dig Liver Dis. 2013;45(4):336–341.
   PubMedGoogle Scholar
• Kang TW, Kim JM, Rhim H, et al. Small hepatocellular carcinoma: radiofrequency ablation versus nonanatomic resection–propensity score analyses of long-term outcomes. Radiology. 2015;275(3):908–919.
   PubMed Web of Science ®Google Scholar
• Kim GA, Shim JH, Kim MJ, et al. Radiofrequency ablation as an alternative to hepatic resection for single small hepatocellular carcinomas. Br J Surg. 2016;103(1):126–135.
   PubMed Web of Science ®Google Scholar
• Yang W, Yan K, Goldberg SN, et al. Ten-year survival of hepatocellular carcinoma patients undergoing radiofrequency ablation as a first-line treatment. World J Gastroenterol. 2016;22(10):2993–3005.
   PubMed Web of Science ®Google Scholar
• Lin Z-Y, Li G-L, Chen J, et al. Effect of heat sink on the recurrence of small malignant hepatic tumors after radiofrequency ablation. J Can Res Ther. 2016;12(supplement):C153–C158.
   PubMed Web of Science ®Google Scholar
• Hou YB, Chen MH, Yan K, et al. Adjuvant percutaneous radiofrequency ablation of feeding artery of hepatocellular carcinoma before treatment. World J Gastroenterol. 2009;15(21):2638–2643.
   PubMed Web of Science ®Google Scholar
• Pillai K, Akhter J, Chua TC, et al. Heat sink effect on tumor ablation characteristics as observed in monopolar radiofrequency, bipolar radiofrequency, and microwave, using ex vivo calf liver model. Medicine (Baltimore). 2015;94(9):e580.
   PubMed Web of Science ®Google Scholar
• Nam SY, Rhim H, Kang TW, et al. Percutaneous radiofrequency ablation for hepatic tumors abutting the diaphragm: clinical assessment of the heat-sink effect of artificial ascites. AJR Am J Roentgenol. 2010;194(2):W227–231.
   PubMed Web of Science ®Google Scholar
• Nakazawa T, Kokubu S, Shibuya A, et al. Radiofrequency ablation of hepatocellular carcinoma: correlation between local tumor progression after ablation and ablative margin. AJR Am J Roentgenol. 2007;188(2):480–488.
   PubMed Web of Science ®Google Scholar
• Xu E-J, Lv S-M, Li K, et al. Immediate evaluation and guidance of liver cancer thermal ablation by three-dimensional ultrasound/contrast-enhanced ultrasound fusion imaging. Int J Hyperthermia. 2018;34(6):870–876.
   PubMed Web of Science ®Google Scholar
• Zhong-Zhen S, Kai L, Rong-Qin Z, et al. A feasibility study for determining ablative margin with 3D-CEUS-CT/MR image fusion after radiofrequency ablation of hepatocellular carcinoma. Ultraschall in Med. 2012;33(07):E250–E255.
   PubMedGoogle Scholar
• Laimer G, Schullian P, Jaschke N, et al. Minimal ablative margin (MAM) assessment with image fusion: an independent predictor for local tumor progression in hepatocellular carcinoma after stereotactic radiofrequency ablation. Eur Radiol. 2020;30(5):2463–2472.
   PubMed Web of Science ®Google Scholar
• Jie T, Guoying F, Gang T, et al. Efficacy and safety of fusion imaging in radiofrequency ablation of hepatocellular carcinoma compared to ultrasound: a meta-analysis. Front Surg. 2021;8:728098.
   PubMed Web of Science ®Google Scholar
• You Y, Zhang M, Li K, et al. Feasibility of 3D US/CEUS-US/CEUS fusion imaging-based ablation planning in liver tumors: a retrospective study. Abdom Radiol. (NY) 2021;46(6):2865–2874.
   PubMed Web of Science ®Google Scholar
• Jiang C, Liu B, Chen S, et al. Safety margin after radiofrequency ablation of hepatocellular carcinoma: precise assessment with a three-dimensional reconstruction technique using CT imaging. Int J Hyperthermia. 2018;34(8):1135–1141.
   PubMed Web of Science ®Google Scholar
• Takeyama N, Mizobuchi N, Sakaki M, et al. Evaluation of hepatocellular carcinoma ablative margins using fused pre- and post-ablation hepatobiliary phase images. Abdom Radiol. (NY). 2019;44(3):923–935.
   PubMed Web of Science ®Google Scholar
• Huang G, Lin M, Xie X, et al. Combined radiofrequency ablation and ethanol injection with a multipronged needle for the treatment of medium and large hepatocellular carcinoma. Eur Radiol. 2014;24(7):1565–1571.
   PubMed Web of Science ®Google Scholar
• Zhao Z, Wu J, Liu X, et al. Insufficient radiofrequency ablation promotes proliferation of residual hepatocellular carcinoma via autophagy. Cancer Lett. 2018;421:73–81.
   PubMed Web of Science ®Google Scholar
• Xu W-L, Wang S-H, Sun W-B, et al. Insufficient radiofrequency ablation-induced autophagy contributes to the rapid progression of residual hepatocellular carcinoma through the HIF-1α/BNIP3 signaling pathway. BMB Rep. 2019;52(4):277–282.
   PubMed Web of Science ®Google Scholar
• Dong S, Kong J, Kong F, et al. Insufficient radiofrequency ablation promotes epithelial-mesenchymal transition of hepatocellular carcinoma cells through Akt and ERK signaling pathways. J Transl Med. 2013;11:273.
   PubMed Web of Science ®Google Scholar
• Yoshida S, Kornek M, Ikenaga N, et al. Sublethal heat treatment promotes epithelial-mesenchymal transition and enhances the malignant potential of hepatocellular carcinoma. Hepatology. 2013;58(5):1667–1680.
   PubMed Web of Science ®Google Scholar
• Zhang N, Li H, Qin C, et al. Insufficient radiofrequency ablation promotes the metastasis of residual hepatocellular carcinoma cells via upregulating flotillin proteins. J Cancer Res Clin Oncol. 2019;145(4):895–907.
   PubMed Web of Science ®Google Scholar
• Weber JC, Navarra G, Jiao LR, et al. New technique for liver resection using heat coagulative necrosis. Ann Surg. 2002;236(5):560–563.
   PubMed Web of Science ®Google Scholar
• Pai M, Frampton AE, Mikhail S, et al. Radiofrequency assisted liver resection: analysis of 604 consecutive cases. Eur J Surg Oncol. 2012;38(3):274–280.
   PubMed Web of Science ®Google Scholar
• Reccia I, Kumar J, Kusano T, et al. Radiofrequency-assisted liver resection: Technique and results. Surg Oncol. 2018;27(3):415–420.
   PubMed Web of Science ®Google Scholar
• Vavra P, Nowakova J, Jelinek P, et al. Radiofrequency-Assisted liver resections: comparison of open and laparoscopic techniques. Hepatogastroenterology. 2014;61(136):2359–2366.
   PubMedGoogle Scholar
• Guo R, Feng X, Xiao S, et al. Short- and long-term outcomes of hepatectomy with or without radiofrequency-assist for the treatment of hepatocellular carcinomas: a retrospective comparative cohort study. Biosci Trends. 2015;9(1):65–72.
   PubMed Web of Science ®Google Scholar
• Curro G, Jiao L, Scisca C, et al. Radiofrequency-assisted liver resection in cirrhotic patients with hepatocellular carcinoma. J Surg Oncol. 2008;98(6):407–410.
   PubMed Web of Science ®Google Scholar
• Li M, Zhang W, Li Y, et al. Radiofrequency-assisted versus clamp-crushing parenchyma transection in cirrhotic patients with hepatocellular carcinoma: a randomized clinical trial. Dig Dis Sci. 2013;58(3):835–840.
   PubMed Web of Science ®Google Scholar
• Sabanovic J, Muhovic S, Rovcanin A, et al. Radiofrequency assisted hepatic parenchyma resection using radiofrequent generator (RF) generator. Acta Inform Med. 2018;26(4):265–268.
   PubMedGoogle Scholar
• Zhang F, Yan J, Feng X-B, et al. Efficiency and safety of radiofrequency-assisted hepatectomy for hepatocellular carcinoma with cirrhosis: a single-center retrospective cohort study. World J Gastroenterol. 2015;21(35):10159–10165.
   PubMed Web of Science ®Google Scholar
• Gerlach TW, Troppmann C, Khatri VP. Major bile duct injury resulting from radiofrequency-assisted hepatectomy. Hepatogastroenterology. 2009;56(91–92):610–614.
   PubMedGoogle Scholar
• Pai M, Spalding D, Jiao L, et al. Use of bipolar radiofrequency in parenchymal transection of the liver, pancreas and kidney. Dig Surg. 2012;29(1):43–47.
   PubMed Web of Science ®Google Scholar
• Ihnat P, Vavra P, Rudinska L, et al. Radiofrequency-assisted liver resection: short-term results in a single institution. Bratisl Lek Listy. 2013;114(1):19–22.
   PubMed Web of Science ®Google Scholar
• Xiao W-K, Chen D, Hu A-B, et al. Radiofrequency-assisted versus clamp-crush liver resection: a systematic review and meta-analysis. J Surg Res. 2014;187(2):471–483.
   PubMed Web of Science ®Google Scholar
• Huang, KW, Jayant K, Lee P-H, et al. Positive Immuno-modulation following radiofrequency assisted liver resection in hepatocellular carcinoma. J Clin Med. 2019;8(3):385.
   PubMed Web of Science ®Google Scholar
• Zhou Y, Ouyang J, Wang Z, et al. A novel internal cold circulation radiofrequency-assisted device for liver transection. Int J Hyperthermia. 2021;38(1):308–315.
   PubMed Web of Science ®Google Scholar
• de Santibanes E, Clavien PA. Playing Play-Doh to prevent postoperative liver failure: the "ALPPS" approach. Ann Surg. 2012;255(3):415–417.
   PubMed Web of Science ®Google Scholar
• Zhang J, Huang H, Bian J, et al. Safety, feasibility, and efficacy of associating liver partition and portal vein ligation for staged hepatectomy in treating hepatocellular carcinoma: a systematic review. Ann Transl Med. 2020;8(19):1246.
   PubMed Web of Science ®Google Scholar
• Wang Q, Yan J, Feng X, et al. Safety and efficacy of radiofrequency-assisted ALPPS (RALPPS) in patients with cirrhosis-related hepatocellular carcinoma. Int J Hyperthermia. 2017;33(7):846–852.
   PubMed Web of Science ®Google Scholar
• Tang K, Zhang B, Dong L, et al. Successful treatment of a huge hepatic carcinoma with right portal vein thrombosis: a case report. Medicine (Baltimore). 2020;99(17):e19636.
   PubMed Web of Science ®Google Scholar
• Rong Z, Lu Q, Yan J. Totally laparoscopic radiofrequency-assisted liver partition with portal vein ligation for hepatocellular carcinoma in cirrhotic liver. Medicine (Baltimore). 2017;96(51):e9432.
   PubMed Web of Science ®Google Scholar
• Wang Q, Chen S, Yan J. Rescue radiofrequency ablation or percutaneous ethanol injection: a strategy for failed RALPPS stage-1 in patients with cirrhosis-related hepatocellular carcinoma. BMC Surg. 2021;21(1):246.
   PubMed Web of Science ®Google Scholar
• Gimenez ME, Houghton EJ, Davrieux CF, et al. Percutaneous radiofrequency assisted liver partition with portal vein embolization for staged hepatectomy (pralpps). Arq Bras Cir Dig. 2018;31(1):e1346.
   PubMed Web of Science ®Google Scholar
• Melekhina O, Efanov M, Alikhanov R, et al. Percutaneous radiofrequency-assisted liver partition versus portal vein embolization before hepatectomy for perihilar cholangiocarcinoma. BJS Open. 2020;4(1):101–108.
   PubMed Web of Science ®Google Scholar
• Llovet JM, Mas X, Aponte JJ, et al. Cost effectiveness of adjuvant therapy for hepatocellular carcinoma during the waiting list for liver transplantation. Gut. 2002;50(1):123–128.
   PubMed Web of Science ®Google Scholar
• Pulvirenti A, Garbagnati F, Regalia E, et al. Experience with radiofrequency ablation of small hepatocellular carcinomas before liver transplantation. Transplant Proc. 2001;33(1-2):1516–1517.
   PubMed Web of Science ®Google Scholar
• Fontana RJ, Humidulluh H, Nghiem H, et al. Percutaneous radiofrequency thermal ablation of hepatocellular carcinoma: a safe and effective bridge to liver transplantation. Liver Transpl. 2002;8(12):1165–1174.
   PubMed Web of Science ®Google Scholar
• Fisher RA, Maluf D, Cotterell AH, et al. Non-resective ablation therapy for hepatocellular carcinoma: effectiveness measured by intention-to-treat and dropout from liver transplant waiting list. Clin Transplant. 2004;18(5):502–512.
   PubMed Web of Science ®Google Scholar
• Schroeder T, Sotiropoulos GC, Molmenti EP, et al. Changes in staging for hepatocellular carcinoma after radiofrequency ablation prior to liver transplantation as found in the explanted liver. Hepatogastroenterology. 2011;58(112):2029–2031.
   PubMedGoogle Scholar
• Panaro F, Piardi T, Audet M, et al. Laparoscopic ultrasound-guided radiofrequency ablation as a bridge to liver transplantation for hepatocellular carcinoma: preliminary results. Transplant Proc. 2010;42(4):1179–1181.
   PubMed Web of Science ®Google Scholar
• N'Kontchou G, Aout M, Laurent A, et al. Survival after radiofrequency ablation and salvage transplantation in patients with hepatocellular carcinoma and Child-Pugh a cirrhosis. J Hepatol. 2012;56(1):160–166.
   PubMed Web of Science ®Google Scholar
• Yao FY, Kerlan RK, Hirose R, et al. Excellent outcome following down-staging of hepatocellular carcinoma prior to liver transplantation: an intention-to-treat analysis. Hepatology. 2008;48(3):819–827.
   PubMed Web of Science ®Google Scholar
• Di Benedetto F, Tarantino G, Montalti R, et al. Laparoscopic radiofrequency ablation in the caudate lobe for hepatocellular carcinoma before liver transplantation. J Laparoendosc Adv Surg Tech A. 2012;22(4):400–402.
   PubMed Web of Science ®Google Scholar
• DuBay DA, Sandroussi C, Kachura JR, et al. Radiofrequency ablation of hepatocellular carcinoma as a bridge to liver transplantation. HPB (Oxford). 2011;13(1):24–32.
   PubMed Web of Science ®Google Scholar
• Liu B, Huang G, Xie X, et al. Feasibility and outcomes of percutaneous radiofrequency ablation for intrahepatic recurrent hepatocellular carcinoma after liver transplantation: a single-center experience. Int J Hyperthermia. 2020;37(1):1202–1209.
   PubMed Web of Science ®Google Scholar
• Yang W, Wu H, Zhang Z-Y, et al. Long-term outcome of percutaneous radiofrequency ablation in recurrent hepatocellular carcinoma after liver transplantation. Int J Hyperthermia. 2018;34(1):68–76.
   PubMed Web of Science ®Google Scholar
• Lee MW, Raman SS, Asvadi NH, et al. Radiofrequency ablation of hepatocellular carcinoma as bridge therapy to liver transplantation: a 10-year intention-to-treat analysis. Hepatology. 2017;65(6):1979–1990.
   PubMed Web of Science ®Google Scholar
• Huang J, Yan L, Wu H, et al. Is radiofrequency ablation applicable for recurrent hepatocellular carcinoma after liver transplantation? J Surg Res. 2016;200(1):122–130.
   PubMed Web of Science ®Google Scholar
• Dai X, Zhao H-Q, Liu R-H, et al. Percutaneous radiofrequency ablation guided by contrast-enhanced ultrasound in treatment of metastatic hepatocellular carcinoma after liver transplantation. Asian Pac J Cancer Prev. 2012;13(8):3709–3712.
   PubMedGoogle Scholar
• Elias D, Debaere T, Muttillo I, et al. Intraoperative use of radiofrequency treatment allows an increase in the rate of curative liver resection. J Surg Oncol. 1998;67(3):190–191.
   PubMed Web of Science ®Google Scholar
• Elias D, Goharin A, El Otmany A, et al. Usefulness of intraoperative radiofrequency thermoablation of liver tumours associated or not with hepatectomy. Eur J Surg Oncol. 2000;26(8):763–769.
   PubMed Web of Science ®Google Scholar
• Choi D, Lim HK, Joh J-W, et al. Combined hepatectomy and radiofrequency ablation for multifocal hepatocellular carcinomas: long-term follow-up results and prognostic factors. Ann Surg Oncol. 2007;14(12):3510–3518.
   PubMed Web of Science ®Google Scholar
• Cheung TT, Ng KK, Chok KS, et al. Combined resection and radiofrequency ablation for multifocal hepatocellular carcinoma: prognosis and outcomes. World J Gastroenterol. 2010;16(24):3056–3062.
   PubMed Web of Science ®Google Scholar
• Lee SJ, Cho E-H, Kim R, et al. Hepatectomy, combined with intraoperative radiofrequency ablation in patients with multiple hepatocellular carcinomas. Korean J Hepatobiliary Pancreat Surg. 2015;19(3):98–102.
   PubMedGoogle Scholar
• Choi D, Lim HK, Rhim H. Concurrent and subsequent radiofrequency ablation combined with hepatectomy for hepatocellular carcinomas. World J Gastrointest Surg. 2010;2(4):137–142.
   PubMedGoogle Scholar
• Hou Y-F, Wei Y-G, Yang J-Y, et al. Combined hepatectomy and radiofrequency ablation versus TACE in improving survival of patients with unresectable BCLC stage B HCC. Hepatobil Pancreat Dis Int. 2016;15(4):378–385.
   PubMed Web of Science ®Google Scholar
• Liu M, Wang K, Wang Y, et al. Short- and long-term outcomes of hepatectomy combined with intraoperative radiofrequency ablation for patients with multiple primarily unresectable colorectal liver metastases: a propensity matching analysis. HPB (Oxford). 2021;23(10):1586–1594.
   PubMed Web of Science ®Google Scholar
• Imai K, Allard M-A, Castro Benitez C, et al. Long-term outcomes of radiofrequency ablation combined with hepatectomy compared with hepatectomy alone for colorectal liver metastases. Br J Surg. 2017;104(5):570–579.
   PubMed Web of Science ®Google Scholar
• Abdelaziz AO, Abdelmaksoud AH, Nabeel MM, et al. Transarterial chemoembolization combined with either radiofrequency or microwave ablation in management of hepatocellular carcinoma. Asian Pac J Cancer Prev. 2017;18(1):189–194.
   PubMedGoogle Scholar
• Mostafa EM, Ganguli S, Faintuch S, et al. Optimal strategies for combining transcatheter arterial chemoembolization and radiofrequency ablation in rabbit VX2 hepatic tumors. J Vasc Interv Radiol. 2008;19(12):1740–1748.
   PubMed Web of Science ®Google Scholar
• Peng Z-W, Zhang Y-J, Chen M-S, et al. Radiofrequency ablation with or without transcatheter arterial chemoembolization in the treatment of hepatocellular carcinoma: a prospective randomized trial. J Clin Oncol. 2013;31(4):426–432.
   PubMed Web of Science ®Google Scholar
• Liu W, Xu H, Ying X, et al. Radiofrequency ablation (RFA) combined with transcatheter arterial chemoembolization (TACE) for patients with medium-to-large hepatocellular carcinoma: a retrospective analysis of long-term outcome. Med Sci Monit. 2020;26:e923263.
   PubMed Web of Science ®Google Scholar
• Lu Z, Wen F, Guo Q, et al. Radiofrequency ablation plus chemoembolization versus radiofrequency ablation alone for hepatocellular carcinoma: a meta-analysis of randomized-controlled trials. Eur J Gastroenterol Hepatol. 2013;25(2):187–194.
   PubMed Web of Science ®Google Scholar
• Kim W, Cho SK, Shin SW, et al. Combination therapy of transarterial chemoembolization (TACE) and radiofrequency ablation (RFA) for small hepatocellular carcinoma: comparison with TACE or RFA monotherapy. Abdom Radiol (NY). 2019;44(6):2283–2292.
   PubMed Web of Science ®Google Scholar
• Bholee AK, Peng K, Zhou Z, et al. Radiofrequency ablation combined with transarterial chemoembolization versus hepatectomy for patients with hepatocellular carcinoma within Milan criteria: a retrospective case-control study. Clin Transl Oncol. 2017;19(7):844–852.
   PubMed Web of Science ®Google Scholar
• Wang W-D, Zhang L-h, Ni J-Y, et al. Radiofrequency ablation combined with transcatheter arterial chemoembolization therapy versus surgical resection for hepatocellular carcinoma within the Milan criteria: a meta-analysis. Korean J Radiol. 2018;19(4):613–622.
   PubMed Web of Science ®Google Scholar
• Liu H, Wang Z-G, Fu S-Y, et al. Randomized clinical trial of chemoembolization plus radiofrequency ablation versus partial hepatectomy for hepatocellular carcinoma within the Milan criteria. Br J Surg. 2016;103(4):348–356.
   PubMed Web of Science ®Google Scholar
• Yuan H, Cao P, Li H-L, et al. Transarterial chemoembolization with radiofrequency ablation versus hepatectomy in hepatocellular carcinoma beyond the Milan criteria: a retrospective study. Cancer Manag Res. 2018;10:5545–5552.
   PubMed Web of Science ®Google Scholar
• Sun Y, Ji S, Ji H, et al. Clinical efficacy analysis of transcatheter arterial chemoembolization (TACE) combined with radiofrequency ablation (RFA) in primary liver cancer and recurrent liver cancer. J Buon. 2019;24:1402–1407.
   PubMed Web of Science ®Google Scholar
• Peng Z, Wei M, Chen S, et al. Combined transcatheter arterial chemoembolization and radiofrequency ablation versus hepatectomy for recurrent hepatocellular carcinoma after initial surgery: a propensity score matching study. Eur Radiol. 2018;28(8):3522–3531.
   PubMed Web of Science ®Google Scholar
• Yuan Z, Wang Y, Hu C, et al. Efficacy of percutaneous thermal ablation combined with transarterial embolization for recurrent hepatocellular carcinoma after hepatectomy and a prognostic nomogram to predict survival. Technol Cancer Res Treat. 2018;17:1533033818801362.
   Web of Science ®Google Scholar
• Yuan P, Wang F, Zhu G, et al. The clinical efficiency of TACE combined with simultaneous computed tomography-guided radiofrequency ablation for advanced hepatocellular carcinoma. Invest New Drugs. 2021;39(5):1383–1388.
   PubMed Web of Science ®Google Scholar
• Zhu D, Yuan D, Wang Z, et al. Efficacy of drug-eluting bead transarterial chemoembolization (DEB-TACE) combined with radiofrequency ablation versus DEB-TACE alone in Chinese hepatocellular carcinoma patients. Medicine (Baltimore). 2019;98(26):e15682.
   PubMed Web of Science ®Google Scholar
• Shimose S, Tanaka M, Iwamoto H, et al. Prognostic impact of transcatheter arterial chemoembolization (TACE) combined with radiofrequency ablation in patients with unresectable hepatocellular carcinoma: Comparison with TACE alone using decision-tree analysis after propensity score matching. Hepatol Res. 2019;49(8):919–928.
   PubMed Web of Science ®Google Scholar
• Bruix J, Takayama T, Mazzaferro V, et al. Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. The Lancet Oncology. 2015;16(13):1344–1354.
   PubMed Web of Science ®Google Scholar
• Kelley RK. Adjuvant sorafenib for liver cancer: wrong stage, wrong dose. Lancet Oncol. 2015;16(13):1279–1281.
   PubMed Web of Science ®Google Scholar
• Zhang W. Sorafenib in adjuvant setting: call for precise and personalized therapy. Transl Gastroenterol Hepatol. 2016;1:13.
   PubMedGoogle Scholar
• Yuan H, Lan Y, Li X, et al. Large hepatocellular carcinoma with local remnants after transarterial chemoembolization: treatment by sorafenib combined with radiofrequency ablation or sorafenib alone. Am J Cancer Res. 2019;9(4):791–799.
   PubMed Web of Science ®Google Scholar
• Feng X, Xu R, Du X, et al. Combination therapy with sorafenib and radiofrequency ablation for BCLC stage 0-B1 hepatocellular carcinoma: a multicenter retrospective cohort study. Am J Gastroenterol. 2014;109(12):1891–1899.
   PubMed Web of Science ®Google Scholar
• Chen L, Liu MX, Cui X. X. Sorafenib combined with radiofrequency ablation as treatment for patients with hepatocellular carcinoma: a systematic review and Meta-analysis. J Buon. 2017;22:1525–1532.
   PubMed Web of Science ®Google Scholar
• Kan X, Jing Y, Wan QY, et al. Sorafenib combined with percutaneous radiofrequency ablation for the treatment of medium-sized hepatocellular carcinoma. Eur Rev Med Pharmacol Sci. 2015;19(2):247–255.
   PubMed Web of Science ®Google Scholar
• Dong S, Kong J, Kong F, et al. Sorafenib suppresses the epithelial-mesenchymal transition of hepatocellular carcinoma cells after insufficient radiofrequency ablation. BMC Cancer. 2015;15:939.
   PubMed Web of Science ®Google Scholar
• Facciorusso A, Abd El Aziz MA, Sacco R. Efficacy of regorafenib in hepatocellular carcinoma patients: a systematic review and meta-analysis. Cancers (Basel). 2019;12(1):36.
   PubMed Web of Science ®Google Scholar
• Abd El Aziz MA, Facciorusso A, Nayfeh T, et al. Immune checkpoint inhibitors for unresectable hepatocellular carcinoma. Vaccines (Basel). 2020;8(4):616.
   PubMed Web of Science ®Google Scholar
• Shi L, Chen L, Wu C, et al. PD-1 blockade boosts radiofrequency ablation-elicited adaptive immune responses against tumor. Clin Cancer Res. 2016;22(5):1173–1184.
   PubMed Web of Science ®Google Scholar
• Fei Q, Pan Y, Lin W, et al. High-dimensional single-cell analysis delineates radiofrequency ablation induced immune microenvironmental remodeling in pancreatic cancer. Cell Death Dis. 2020;11(7):589.
   PubMed Web of Science ®Google Scholar
• Shi L, Wang J, Ding N, et al. Inflammation induced by incomplete radiofrequency ablation accelerates tumor progression and hinders PD-1 immunotherapy. Nat Commun. 2019;10(1):5421.
   PubMed Web of Science ®Google Scholar
• Liu Z, Zhou Y, Zhang P, et al. Meta-analysis of the therapeutic effect of hepatectomy versus radiofrequency ablation for the treatment of hepatocellular carcinoma. Surg Laparosc Endosc Percutan Tech. 2010;20(3):130–140.
   PubMed Web of Science ®Google Scholar
• Huang J, Yan L, Cheng Z, et al. A randomized trial comparing radiofrequency ablation and surgical resection for HCC conforming to the Milan criteria. Ann Surg. 2010;252(6):903–912.
   PubMed Web of Science ®Google Scholar
• Feng K, Yan J, Li X, et al. A randomized controlled trial of radiofrequency ablation and surgical resection in the treatment of small hepatocellular carcinoma. J Hepatol. 2012;57(4):794–802.
   PubMed Web of Science ®Google Scholar
• Chen MS, Li J-Q, Zheng Y, et al. A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma. Ann Surg. 2006;243(3):321–328.
   PubMed Web of Science ®Google Scholar
• Livraghi T, Meloni F, Di Stasi M, et al. Sustained complete response and complications rates after radiofrequency ablation of very early hepatocellular carcinoma in cirrhosis: is resection still the treatment of choice? Hepatology. 2008;47(1):82–89.
   PubMed Web of Science ®Google Scholar
• Cucchetti A, Piscaglia F, Cescon M, et al. Cost-effectiveness of hepatic resection versus percutaneous radiofrequency ablation for early hepatocellular carcinoma. J Hepatol. 2013;59(2):300–307.
   PubMed Web of Science ®Google Scholar
• Imai K, Beppu T, Chikamoto A, et al. Comparison between hepatic resection and radiofrequency ablation as first-line treatment for solitary small-sized hepatocellular carcinoma of 3 cm or less. Hepatol Res. 2013;43(8):853–864.
   PubMed Web of Science ®Google Scholar
• Fu C, Liu N, Deng Q, et al. Radiofrequency ablation vs. surgical resection on the treatment of patients with small hepatocellular carcinoma: a system review and meta-analysis of five randomized controlled trials. Hepatogastroenterology. 2014;61(134):1722–1729.
   PubMedGoogle Scholar
• Dong W, Zhang T, Wang ZG, et al. Clinical outcome of small hepatocellular carcinoma after different treatments: a Meta-analysis. World J Gastroenterol. 2014;20(29):10174–10182.
   PubMed Web of Science ®Google Scholar
• Xu XL, Liu XD, Liang M, et al. Radiofrequency ablation versus hepatic resection for small hepatocellular carcinoma: systematic review of randomized controlled trials with meta-analysis and trial sequential analysis. Radiology. 2018;287(2):461–472.
   PubMed Web of Science ®Google Scholar
• Nishikawa H, Kimura T, Kita R, et al. Radiofrequency ablation for hepatocellular carcinoma. Int J Hyperthermia. 2013;29(6):558–568.
   PubMed Web of Science ®Google Scholar
• Minami Y, Kudo M. Radiofrequency ablation of hepatocellular carcinoma: current status. World J Radiol. 2010;2(11):417–424.
   PubMedGoogle Scholar
• Jia Z, Zhang H, Li N. Evaluation of clinical outcomes of radiofrequency ablation and surgical resection for hepatocellular carcinoma conforming to the Milan criteria: a systematic review and meta-analysis of recent randomized controlled trials. J Gastroenterol Hepatol. 2021;36(7):1769–1777.
   PubMed Web of Science ®Google Scholar
• Wang Q, Tang M, Zhang S. Comparison of radiofrequency ablation and surgical resection for hepatocellular carcinoma conforming to the Milan criteria: a meta-analysis. ANZ J Surg. 2021;91(7–8):E432–E438.
   PubMed Web of Science ®Google Scholar
• Xuan D, Wen W, Xu D, et al. Survival comparison between radiofrequency ablation and surgical resection for patients with small hepatocellular carcinoma: a systematic review and meta-analysis. Medicine (Baltimore). 2021;100(7):e24585.
   PubMed Web of Science ®Google Scholar
• Conticchio M, Inchingolo R, Delvecchio A, et al. Radiofrequency ablation vs. surgical resection in elderly patients with hepatocellular carcinoma in milan criteria. World J Gastroenterol. 2021;27(18):2205–2218.
   PubMed Web of Science ®Google Scholar
• Xia Y, Li J, Liu G, et al. Long-term effects of repeat hepatectomy vs percutaneous radiofrequency ablation among patients with recurrent hepatocellular carcinoma: a randomized clinical trial. JAMA Oncol. 2020;6(2):255–263.
   PubMed Web of Science ®Google Scholar
• Yang D, Zhuang B, Wang Y, et al. Radiofrequency ablation versus hepatic resection for recurrent hepatocellular carcinoma: an updated meta-analysis. BMC Gastroenterol. 2020;20(1):402.
   PubMed Web of Science ®Google Scholar
• Mironov O, Jaberi A, Kachura JR. Thermal ablation versus surgical resection for the treatment of stage T1 hepatocellular carcinoma in the surveillance, epidemiology, and end results database population. J Vasc Interv Radiol. 2017;28(3):325–333.
   PubMed Web of Science ®Google Scholar
• Lee S, Kang TW, Song KD, et al. Effect of microvascular invasion risk on early recurrence of hepatocellular carcinoma after surgery and radiofrequency ablation. Ann Surg. 2021;273(3):564–571.
   PubMed Web of Science ®Google Scholar
• Lee S, Kang TW, Cha DI, et al. Radiofrequency ablation vs. surgery for perivascular hepatocellular carcinoma: propensity score analyses of long-term outcomes. J Hepatol. 2018;69(1):70–78.
   PubMed Web of Science ®Google Scholar
• Facciorusso A, Abd El Aziz MA, Tartaglia N, et al. Microwave ablation versus radiofrequency ablation for treatment of hepatocellular carcinoma: a meta-analysis of randomized controlled trials. Cancers (Basel). 2020;12(12):3796.
   PubMed Web of Science ®Google Scholar
• Izzo F, Granata V, Grassi R, et al. Radiofrequency ablation and microwave ablation in liver tumors: an Update. Oncologist. 2019;24(10):e990–e1005.
   PubMed Web of Science ®Google Scholar
• Poggi G, Tosoratti N, Montagna B, et al. Microwave ablation of hepatocellular carcinoma. World J Hepatol. 2015;7(25):2578–2589.
   PubMed Web of Science ®Google Scholar
• Lucchina N, Tsetis D, Ierardi AM, et al. Current role of microwave ablation in the treatment of small hepatocellular carcinomas. Ann Gastroenterol. 2016;29(4):460–465.
   PubMedGoogle Scholar
• Glassberg MB, Ghosh S, Clymer JW, et al. Microwave ablation compared with radiofrequency ablation for treatment of hepatocellular carcinoma and liver metastases: a systematic review and Meta-analysis. Onco Targets Ther. 2019;12:6407–6438.
   PubMed Web of Science ®Google Scholar
• Xu Y, Shen Q, Wang N, et al. Microwave ablation is as effective as radiofrequency ablation for very-early-stage hepatocellular carcinoma. Chin J Cancer. 2017;36(1):14.
   PubMedGoogle Scholar
• Tan W, Deng Q, Lin S, et al. Comparison of microwave ablation and radiofrequency ablation for hepatocellular carcinoma: a systematic review and meta-analysis. Int J Hyperthermia. 2019;36(1):264–272.
   PubMed Web of Science ®Google Scholar
• Vietti Violi N, Duran R, Guiu B, et al. Efficacy of microwave ablation versus radiofrequency ablation for the treatment of hepatocellular carcinoma in patients with chronic liver disease: a randomised controlled phase 2 trial. Lancet Gastroenterol Hepatol. 2018;3(5):317–325.
   PubMed Web of Science ®Google Scholar
• Yap S, Cheong JKK, Ooi EH, et al. A numerical study on the no-touch bipolar radiofrequency ablation. Annu Int Conf IEEE Eng Med Biol Soc. 2019;2019:2887–2890.
   PubMedGoogle Scholar
• Chai Y, Li K, Zhang C, et al. The short-term efficacy of no-touch radiofrequency ablation in treating cirrhosis-based small hepatocellular carcinoma. BMC Cancer. 2019;19(1):497.
   PubMed Web of Science ®Google Scholar
• Suh YS, Choi JW, Yoon JH, et al. No-Touch vs. Conventional radiofrequency ablation using twin internally cooled wet electrodes for small hepatocellular carcinomas: a randomized prospective comparative Study. Korean J Radiol. 2021;22(12):1974–1984.
   PubMed Web of Science ®Google Scholar
• Mohkam K, Dumont P-N, Manichon A-F, et al. No-touch multibipolar radiofrequency ablation vs. surgical resection for solitary hepatocellular carcinoma ranging from 2 to 5cm. J Hepatol. 2018;68(6):1172–1180.
   PubMed Web of Science ®Google Scholar
• Kim T-H, Choi HI, Kim BR, et al. No-Touch radiofrequency ablation of VX2 hepatic tumors in vivo in rabbits: a proof of concept study. Korean J Radiol. 2018;19(6):1099–1109.
   PubMed Web of Science ®Google Scholar
• Kawamura Y, Ikeda K, Shindoh J, et al. No-touch ablation in hepatocellular carcinoma has the potential to prevent intrasubsegmental recurrence to the same degree as surgical resection. Hepatol Res. 2019;49(2):164–176.
   PubMed Web of Science ®Google Scholar
• Hocquelet A, Aubé C, Rode A, et al. Comparison of no-touch multi-bipolar vs. monopolar radiofrequency ablation for small HCC. J Hepatol. 2017;66(1):67–74.
   PubMed Web of Science ®Google Scholar
• Seror O, N'Kontchou G, Nault JC, Rabahi Y, et al. Hepatocellular carcinoma within milan criteria: No-Touch multibipolar radiofrequency ablation for Treatment-Long-term results. Radiology. 2016;280(2):611–621.
   PubMed Web of Science ®Google Scholar
• Lee DH, Lee MW, Kim PN, et al. Outcome of No-Touch Radiofrequency Ablation for Small Hepatocellular Carcinoma: A Multicenter Clinical Trial. Radiology. 2021;301(1):229–236.
   PubMed Web of Science ®Google Scholar
• Hirooka M, Hiraoka A, Ochi H, et al. Prospective cohort trial to confirm the efficacy of no-touch radio frequency ablation. J Gastroenterol Hepatol. 2019;34(3):567–574.
   PubMed Web of Science ®Google Scholar
• Park S-J, Cho EJ, Lee J-H, et al. Switching monopolar No-Touch radiofrequency ablation using octopus electrodes for small hepatocellular carcinoma: a randomized clinical trial. Liver Cancer. 2021;10(1):72–81.
   PubMed Web of Science ®Google Scholar
• Cardinal J, Klune JR, Chory E, et al. Noninvasive radiofrequency ablation of cancer targeted by gold nanoparticles. Surgery. 2008;144(2):125–132.
   PubMed Web of Science ®Google Scholar
• Beyk J, Tavakoli H. Selective radiofrequency ablation of tumor by magnetically targeting of multifunctional iron oxide-gold nanohybrid. J Cancer Res Clin Oncol. 2019;145(9):2199–2209.
   PubMed Web of Science ®Google Scholar
• Fazal S, Paul-Prasanth B, Nair SV, et al. Theranostic iron oxide/gold ion nanoprobes for MR imaging and noninvasive RF hyperthermia. ACS Appl Mater Interfaces. 2017;9(34):28260–28272.
   PubMed Web of Science ®Google Scholar
• Jose A, Surendran M, Fazal S, et al. Multifunctional fluorescent iron quantum clusters for non-invasive radiofrequency ablation of cancer cells. Colloids Surf B Biointerfaces. 2018;165:371–380.
   PubMed Web of Science ®Google Scholar
• Glazer ES, Curley SA. Non-invasive radiofrequency ablation of malignancies mediated by quantum dots, gold nanoparticles and carbon nanotubes. Ther Deliv. 2011;2(10):1325–1330.
   PubMedGoogle Scholar
• Pedro RN, Thekke-Adiyat T, Goel R, et al. Use of tumor necrosis factor-alpha-coated gold nanoparticles to enhance radiofrequency ablation in a translational model of renal tumors. Urology. 2010;76(2):494–498.
   PubMed Web of Science ®Google Scholar
• Morishita A, Sakamoto T, Kobara H, et al. Evaluation of in vivo efficacy of radiofrequency ablation with D-sorbitol in animal liver. Mol Clin Oncol. 2016;4(2):183–186.
   PubMedGoogle Scholar
• Chen Z, Zhao H, Qiao X, et al. Effect of Microbubble-Enhanced ultrasound on radiofrequency ablation of rabbit liver. Ultrasound Med Biol. 2018;44(7):1451–1459.
   PubMed Web of Science ®Google Scholar
• Dan J-Q, Zhang Y-J, Huang J-T, et al. Hepatitis B virus reactivation after radiofrequency ablation or hepatic resection for HBV-related small hepatocellular carcinoma: a retrospective study. Eur J Surg Oncol. 2013;39(8):865–872.
   PubMed Web of Science ®Google Scholar
• Meredith K, Haemmerich D, Qi C, et al. Hepatic resection but not radiofrequency ablation results in tumor growth and increased growth factor expression. Ann Surg. 2007;245(5):771–776.
   PubMed Web of Science ®Google Scholar
• Waitz R, Solomon SB. Can local radiofrequency ablation of tumors generate systemic immunity against metastatic disease? Radiology. 2009;251(1):1–2.
   PubMed Web of Science ®Google Scholar
• Haen SP, Pereira PL, Salih HR, et al. More than just tumor destruction: immunomodulation by thermal ablation of cancer. Clin Dev Immunol. 2011;2011:160250.
   PubMed Web of Science ®Google Scholar
• Greten TF, Korangy F. Radiofrequency ablation for the treatment of HCC-maybe much more than simple tumor destruction? J Hepatol. 2010;53(4):775–776.
   PubMed Web of Science ®Google Scholar
• Zerbini A, Pilli M, Penna A, et al. Radiofrequency thermal ablation of hepatocellular carcinoma liver nodules can activate and enhance tumor-specific T-cell responses. Cancer Res. 2006;66(2):1139–1146.
   PubMed Web of Science ®Google Scholar
• Zerbini A, Pilli M, Laccabue D, et al. Radiofrequency thermal ablation for hepatocellular carcinoma stimulates autologous NK-cell response. Gastroenterology. 2010;138(5):1931–1942.
   PubMed Web of Science ®Google Scholar
• Nijkamp MW, van der Bilt JDW, de Bruijn MT, et al. Accelerated perinecrotic outgrowth of colorectal liver metastases following radiofrequency ablation is a hypoxia-driven phenomenon. Ann Surg. 2009;249(5):814–823.
   PubMed Web of Science ®Google Scholar
• Nijkamp MW, Hoogwater FJH, Steller EJA, et al. CD95 is a key mediator of invasion and accelerated outgrowth of mouse colorectal liver metastases following radiofrequency ablation. J Hepatol. 2010;53(6):1069–1077.
   PubMed Web of Science ®Google Scholar
• Ke S, Ding X-M, Kong J, et al. Low temperature of radiofrequency ablation at the target sites can facilitate rapid progression of residual hepatic VX2 carcinoma. J Transl Med. 2010;8(1):73.
   PubMed Web of Science ®Google Scholar
• Thompson SM, Callstrom MR, Jondal DE, et al. Heat stress-induced PI3K/mTORC2-dependent AKT signaling is a central mediator of hepatocellular carcinoma survival to thermal ablation induced heat stress. PLOS One. 2016;11(9):e0162634.
   PubMed Web of Science ®Google Scholar
• Kong J, Yao C, Dong S, et al. ICAM-1 activates platelets and promotes endothelial permeability through VE-Cadherin after insufficient radiofrequency ablation. Adv Sci (Weinh). 2021;8(4):2002228.
   PubMedGoogle Scholar
• Kong J, Yao C, Ding X, et al. ATPase inhibitory factor 1 promotes hepatocellular carcinoma progression after insufficient radiofrequency ablation, and attenuates cell sensitivity to sorafenib Therapy. Front Oncol. 2020;10:1080.
   PubMed Web of Science ®Google Scholar
• Deng Q, Chen S, Fu C, et al. Long noncoding RNA expression profiles in sub-lethal heat-treated hepatoma carcinoma cells. World J Surg Oncol. 2017;15(1):136.
   PubMed Web of Science ®Google Scholar